List view / Grid view
24 March 2014 | By The European Medicines Agency
Vynfinit (vintafolide) offers treatment for women with limited therapeutic options; two diagnostic medicines recommended for approval will help identify patients most likely to respond...
24 March 2014 | By The European Medicines Agency
This page provides an overview of the opinions adopted at the March 2014 meeting of the Committee for Medicinal Products for Human Use and other important outcomes...
21 March 2014 | By Boehringer Ingelheim
Positive opinion for investigational SGLT2 inhibitor empagliflozin for the treatment of T2D in adults...
21 March 2014 | By The European Medicines Agency
Entyvio (vedolizumab) offers a treatment option for patients who do not respond to standard therapies...
28 February 2014 | By Merck
Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of a new, investigational tablet formulation of NOXAFIL®...
25 February 2014 | By The European Medicines Agency
Over the past twelve months, a total of 12 medicines for the treatment of rare diseases were recommended for marketing authorisation by the European Medicines Agency’s Committee for Medicinal Products for Human Use...
21 February 2014 | By The European Medicines Agency
The European Medicines Agency has concluded its review of Protelos/Osseor and has recommended further restricting the use of the medicine to patients who cannot be treated with other medicines approved for osteoporosis...
21 February 2014 | By Teva Pharmaceutical Industries Ltd
Innovative new inhaler for asthma and COPD patients
Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xolair®...
21 November 2013 | By GlaxoSmithKline
“We welcome the CHMP’s positive opinion on dolutegravir – it puts us a step closer to offering this new treatment option to people across Europe who are living with HIV...”
22 March 2013 | By Gilead Sciences
Stribild® a once-daily integrase inhibitor-based single tablet regimen for the treatment of HIV-1 infection...
18 January 2013 | By Novartis
"Novartis welcomes the decision by the CHMP in support of the approval of Ilaris in the EU"
16 November 2012 | By Sanofi
“The CHMP positive opinion for Lyxumia marks an important milestone..."
16 November 2012 | By Novartis
The CHMP of the EMA adopted a positive opinion for Exjade®...
16 November 2012 | By Novartis
The CHMP of the EMA has adopted a positive opinion for Bexsero for use in individuals from 2 months of age and older...
